Online citations, reference lists, and bibliographies.

Brain Carcinoid Metastases: Outcomes And Prognostic Factors.

Grant W. Mallory, Shanna Fang, Caterina Giannini, Jamie J Van Gompel, Ian F. Parney
Published 2013 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECT Carcinoid tumors are rare and have generally been regarded as indolent neoplasms. Systemic disease is often incurable; however, patients may live years with this disease. Furthermore, metastatic brain lesions are extremely uncommon. As such, few series have examined outcomes and prognostic factors in those with brain involvement. METHODS The authors performed a retrospective review of patients who underwent primary treatment at Mayo Clinic in Rochester, Minnesota, for metastatic carcinoid tumors to the brain between 1986 and 2011. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier statistics. Cox proportional hazards were used to determine predictors of survival. RESULTS Fifteen patients underwent primary treatment for metastatic carcinoid tumors to the brain between 1986 and 2011. Their mean age was 58 ± 12 years. Eighty percent (n = 12) of patients underwent surgery, whereas 2 received stereotactic radiosurgery and 1 had whole-brain radiation therapy (WBRT) as the primary treatment. The median follow-up duration was 19 months (maximum 124 months). Systemic disease progression occurred in 73% and was the leading cause of death in known cases, while intracranial disease recurred in 40%. The median PFS and OS were 21 and 19 months, respectively. The use of adjuvant WBRT correlated with improved PFS (HR 0.15, CI 0.0074-0.95, p = 0.044). Those who underwent surgery as primary modalities trended toward longer progression-free intervals (p = 0.095), although this did not reach significance. CONCLUSIONS Metastatic carcinoid disease to the brain appears to have a worse prognosis than that of other extracranial metastases. Although there was a trend toward a survival advantage in patients who underwent surgery and WBRT, further study is needed to establish definitive treatment recommendations.
This paper references
10.1023/B:NEON.0000014517.56866.bc
Single Brain Metastases of Carcinoid Tumors
F. Maiuri (2004)
10.1002/cncr.25425
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Jonathan R Strosberg (2011)
10.1016/J.CLON.2011.08.006
The management of neuroendocrine tumours: current and future medical therapy options.
Kjell E Öberg (2012)
Unusually aggressive rectal carcinoid metastasizing to larynx, pancreas, adrenal glands, and brain.
Dimitrios Danikas (2000)
10.1002/1097-0142(19950315)75:6<1386::AID-CNCR2820750622>3.0.CO;2-U
Radiation therapy in the management of patients with malignant carcinoid tumors.
Anuradha Chakravarthy (1995)
10.1200/JCO.2007.15.4377
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
James C. Yao (2008)
10.4103/2152-7806.82250
Brain metastasis from large cell neuroendocrine carcinoma of the urinary bladder
Atsushi Tsugu (2011)
10.1093/annonc/mdl105
Rationale for the use of somatostatin analogs as antitumor agents.
C. Susini (2006)
10.1016/S1072-7515(98)00099-4
Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?
H. Chen (1998)
10.1200/JCO.2009.22.8585
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
David L. Bushnell (2010)
10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4
Carcinoid tumors. An analysis of 2,837 cases.
J. Godwin (1975)
10.1002/1097-0142(194911)2:6<1005::AID-CNCR2820020608>3.0.CO;2-1
Carcinoid tumors; a re-emphasis of their malignant nature; review of 140 cases.
Carl M. Pearson (1949)
10.1159/000151222
Parathyroid Hormone-Related Peptide-Secreting Pancreatic Neuroendocrine Tumours: Case Series and Literature Review
R. Srirajaskanthan (2008)
10.1056/NEJM199002223220802
A randomized trial of surgery in the treatment of single metastases to the brain.
R. Patchell (1990)
10.1056/NEJMoa1003825
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond (2011)
10.1016/S1054-3589(08)60656-0
Pharmacologic and endocrine aspects of carcinoid syndrome.
John A. Oates (1967)
10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2
An analysis of 8305 cases of carcinoid tumors.
Irvin Mark Modlin (1997)
10.1016/0360-3016(91)90061-8
The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors.
Karen D. Schupak (1991)
10.1212/WNL.36.6.745
Neurologic complications of carcinoid
Roy A. Patchell (1986)
10.1001/archsurg.1982.01380290176031
Carcinoid tumors: a 37-year experience.
J Zeitels (1982)
10.1056/NEJM198605013141803
Secretion of chromogranin A by peptide-producing endocrine neoplasms.
D. O'Connor (1986)
10.1002/ana.410330605
Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?
C. Vecht (1993)
10.1210/jcem.78.1.7904612
A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome.
S. Lamberts (1994)
10.1200/JCO.2009.22.8510
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
A. Rinke (2009)
Highly aggressive policy of hepatic resections for neuroendocrine liver metastases.
G. Grazi (2000)
10.1002/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V
Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.
M L Fjällskog (2001)
10.1067/msy.2003.114
Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study.
Dominique M Elias (2003)
10.1097/JTO.0b013e3181861d7b
Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007
Eric T. K. Lim (2008)
10.1007/BF02385898
Carcinoids of the rectum: An evaluation of 1271 reported cases
J. Soga (2006)
10.1007/s00268-003-7019-3
Gastrointestinal Carcinoid Tumors: Factors that Predict Outcome
J. J. Gompel (2003)
10.1016/S0140-6736(63)90951-6
THE CLASSIFICATION OF CARCINOID TUMOURS
E D Williams (1963)
10.1007/s12032-011-9986-9
Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature
Mutlu Dogan (2011)
10.3171/jns.1990.73.1.0130
Metastatic intracranial carcinoid with immunohistochemical observation. Case report.
Takachika Ozawa (1990)
10.1016/J.YGAS.2011.07.146
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Randall K. Pearson (2011)
10.1016/S0140-6736(84)90320-9
TREATMENT OF METASTASISING GRF-PRODUCING TUMOUR WITH A LONG-ACTING SOMATOSTATIN ANALOGUE
K. v. Werder (1984)
Carcinoid metastasis to the brain 895 testinal carcinoid tumors: factors that predict outcome
JJ SrVanGompel (2013)
10.1097/MPA.0b013e3181ec124e
The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems
David S Klimstra (2010)
10.1073/pnas.87.17.6762
Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin.
William A. Banks (1990)
10.1001/archinte.1982.00340220141023
Carcinoid tumor of the gastrointestinal tract with metastases to the brain.
FredJ. Schiffman (1982)
10.1002/cncr.20592
Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Shawn D. Safford (2004)
Medical progress : Carcinoid tumors
Matthew H. Kulke (1999)
Karzinoide Tumoren des Dunndarms
Stefan Oberndorfer (1907)
10.1016/0002-9610(83)90136-8
Carcinoids and the carcinoid syndrome.
T. Wareing (1983)
10.1056/NEJM198011203032101
Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.
C. Moertel (1980)
10.1097/01.sla.0000129342.67174.67
Updated Population-Based Review of Carcinoid Tumors
M. Maggard (2004)
10.1056/nejm199903183401107
Carcinoid tumors.
M. Kulke (1999)
10.1056/NEJM199202203260804
Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.
C. Moertel (1992)
10.1002/cncr.20659
Carcinoid metastasis to the brain.
R. Hlatký (2004)
10.1136/gutjnl-2011-300831
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
J. Ramage (2011)
10.1159/000335557
Typical Bronchial Carcinoid Metastasizing to the Brain: A Case Presentation
Simon Blechman Zeichner (2011)
10.1001/jama.280.17.1485
Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial.
Roy A. Patchell (1998)



This paper is referenced by
10.1053/j.semnuclmed.2015.12.003
Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.
Lisa Bodei (2016)
10.1148/rg.2017160113
Multimodality Imaging Findings in Carcinoid Tumors: A Head-to-Toe Spectrum.
Ameya Jagdish Baxi (2017)
10.14791/btrt.2018.6.e18
Pheochromocytoma with Brain Metastasis: A Extremely Rare Case in Worldwide
Yun seong Cho (2018)
10.1016/j.jclinane.2015.08.014
Anesthetic management of patients undergoing resection of carcinoid metastasis to the brain.
Tasha L Welch (2016)
10.1080/02688697.2017.1327018
More than meets the MRI: case report of a carcinoid tumour metastasis mimicking a meningioma
Conrad Harrison (2019)
10.1210/jc.2014-1732
Von hippel-lindau disease associated pulmonary carcinoid with cranial metastasis.
C. Zhang (2014)
10.1186/s12885-015-1999-x
Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain
J. Akimoto (2015)
10.1093/NOP/NPX009
Outcomes of stereotactic radiosurgery of brain metastases from neuroendocrine tumors.
Anussara Prayongrat (2018)
10.1136/bcr-2019-230582
Primary neuroendocrine carcinoma of the brain
Clay T Reed (2019)
10.1186/s12883-019-1310-x
Neuroendocrine carcinoma of the colon presenting as acute meningitis
Julie R Bloom (2019)
10.1155/2015/847058
Metastatic Extrapulmonary Small Cell Carcinoma to the Cerebellopontine Angle: A Case Report and Review of the Literature
D Theodros (2015)
10.1016/j.clon.2018.03.006
External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review.
David L Chan (2018)
10.1186/s13256-019-2214-5
Unusual skull base metastasis from neuroendocrine tumor: a case report
Kok Haw Jonathan Lim (2019)
10.1055/a-0604-2924
[Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27].
Anja Rinke (2018)
10.12659/PJR.899007
Disseminated Pancreatic Neuroendocrine Neoplasm (NEN) with an Uncommon Localisation in the Central Nervous System. A Case Report
Joanna Białkowska (2017)
10.1159/000402936
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
L. Bodei (2015)
10.1055/A-0604-2924
S2k-Leitlinie Neuroendokrine Tumore
Verdauungs und Stoffwechselkrankheiten Deutsche Gesellschaft Gastroenterologie (2018)
10.1186/s12885-019-5559-7
Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome
Sebastian Krug (2019)
10.1016/j.thorsurg.2014.04.005
Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
L. Bodei (2014)
Semantic Scholar Logo Some data provided by SemanticScholar